Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel
Uitgebreid zoeken

Radio Pharming !

45.776 Posts
Pagina: «« 1 ... 2088 2089 2090 2091 2092 ... 2289 »» | Laatste | Omlaag ↓
  1. forum rang 6 Jager63 3 augustus 2023 07:19

    • Jager63

      Lid sinds: 09 okt 2020

      Laatste bezoek: 11 jun 2025

    • Aanbevelingen

      Ontvangen: 4465

      Gegeven: 1422

    •    Aantal posts: 15.493

    Pharming Group reports second quarter and first half 2023 financial results

    RUCONEST® business performed strongly in 2Q 2023; continue to anticipate low single digit annual revenue growth
    Strong start to U.S. Joenja® launch during 2Q 2023; 43 patients on paid therapy and US$3.8 million revenue
    1H 2023 revenues increased 1% to US$97.4 million, compared to 1H 2022
    2Q 2023 revenues increased 9% to US$54.9 million, compared to 2Q 2022, driven by strong RUCONEST® revenues and the U.S. commercial launch of Joenja®
    RUCONEST® revenues increased 20% in 2Q 2023 to US$51.1 million, compared to 1Q 2023, but decreased 3% in 1H 2023 compared to 1H 2022
    Overall cash and cash equivalents, including restricted cash, of US$194.1 million at the end of 2Q 2023, compared to US$186.2 million at end of 1Q 2023
    Strong progress in efforts to make leniolisib available to APDS patients in key markets globally - CHMP opinion expected 4Q 2023, regulatory submissions filed in Canada, Australia, and Israel, and named patient program launched
    Leiden, The Netherlands, August 3, 2023
    Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) presents its preliminary (unaudited) financial report for the second quarter and first half ended June 30, 2023.

    Chief Executive Officer, Sijmen de Vries, commented:
    "The second quarter of 2023 was strong for Pharming. After the reimbursement disruptions experienced in the HAE market in the first quarter, RUCONEST® recovered significantly in the second quarter increasing 20% over the first quarter of 2023. Our RUCONEST® business performed well across a variety of leading revenue indicators, positioning us well for the second half of the year. RUCONEST® continues to provide a stable base for Pharming's future growth, and we continue to foresee low single digit growth in sales for the year.

    The Joenja® (leniolisib) U.S. launch got off to a strong start with the first reimbursed shipments to patients taking place in April; within two weeks of FDA approval. Our focus throughout the second quarter was enrolling identified U.S.-based APDS patients on Joenja® and working with payors on reimbursement. As of June 30, we have 60 patient enrollments and 43 patients on paid therapy, and US$3.8 million in associated revenues for the second quarter.

    We continue to make good progress in identifying additional patients with APDS in key global markets. We have now identified over 640 patients in markets including the U.S., Europe, the U.K., Japan, Canada, Australia and Israel.

    Through our regulatory, clinical, patient finding, and genetic testing efforts, we continue to make significant progress towards our goal of bringing this disease modifying treatment to adult and pediatric APDS patients worldwide.

    Pharming's progress continues to aid our patients and stakeholders as we focus on, and invest in, the long term growth of the company. I am immensely proud of our teams' many achievements in the first half of 2023."
45.776 Posts
Pagina: «« 1 ... 2088 2089 2090 2091 2092 ... 2289 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.286
AB InBev 2 5.562
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 53.189
ABO-Group 1 27
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 11.524
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 196
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 18.032
Aedifica 3 995
Aegon 3.258 323.525
AFC Ajax 538 7.105
Affimed NV 2 6.355
ageas 5.844 109.944
Agfa-Gevaert 14 2.092
Ahold 3.538 74.431
Air France - KLM 1.025 35.658
AIRBUS 1 13
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.108
Alfen 17 26.902
Allfunds Group 4 1.564
Almunda Professionals (vh Novisource) 651 4.255
Alpha Pro Tech 1 17
Alphabet Inc. 1 441
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.487 114.835
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.841 245.788
AMG 972 135.675
AMS 3 73
Amsterdam Commodities 305 6.807
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 507
Antonov 22.632 153.605
Aperam 92 15.222
Apollo Alternative Assets 1 17
Apple 5 400
Arcadis 252 8.899
Arcelor Mittal 2.037 321.489
Archos 1 1
Arcona Property Fund 1 301
arGEN-X 17 10.557
Aroundtown SA 1 227
Arrowhead Research 5 9.785
Ascencio 1 35
ASIT biotech 2 697
ASMI 4.108 39.942
ASML 1.767 116.646
ASR Nederland 21 4.545
ATAI Life Sciences 1 7
Atenor Group 1 547
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 33 15.466
Axsome Therapeutics 1 177
Azelis Group 1 79
Azerion 7 3.572

Macro & Bedrijfsagenda

  1. 16 juni

    1. Industriële productie mei (Chi)
    2. Detailhandelsverkopen mei (Chi)
    3. Aegon ex-dividend
    4. Handelsbalans april (eur)
    5. Maandrapport OPEC (Oos)
    6. Empire State index juni (VS)

  2. 17 juni

    1. Onward Medical Q1-cijfers
    2. Bank of Japan rentebesluit (Jap)
    3. Colruyt jaarcijfers
    4. ZEW economisch sentiment juni (Dld)
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht
Naar de hele agenda